During a Case-Based Roundtable® event, Andrew H. Lipsky, MD, moderated a discussion on the efficacy and safety of newer BTK ...

John Strickler, MD, discusses targeting c-Met as a biomarker in gastric and gastroesophageal junction cancers.

In an interview with Targeted Oncology, Courtney Van Houzen, PharmD, shared her experience in bringing bispecific antibody ...

Meredith McKean, MD, MPH, discussed findings from a longer-term follow-up study evaluating fianlimab plus cemiplimab for the ...

Eric Cheung, DO, Targeted Oncology’s second 2024 Oncology Icon, discussed his journey in oncology, advances in treatment, and ...

Amy Selly, CNP, AOCNP, discusses how physicians can support their patients' survivorship journeys.

John M. Burke, MD, examines how new obesity treatments, such as GLP-1 agonists, might influence future cancer rates.

According to findings from the TALAPRO-2 study, the combination led to significant and meaningful improvements in overall ...

The approval of inavolisib is supported by findings from the phase 3 INAVO120 study evaluating the agent plus palbociclib and ...

Samer A. Al'Hadidi, MD, MS, reviewed the benefits of cilta-cel in the subgroup analysis of CARTITUDE-4 in patients with ...

The first patient with advanced gastric and gastroesophageal cancer has been dosed in a trial combining PT886 with ...

Ana Baramidze, MD, PhD, discussed 5-year follow-up results from the EMPOWER-Lung study evaluating cemiplimab vs chemotherapy ...